GLENMARK PHARMACEUTICALS
|
The Current P/S Ratio of GLENMARK PHARMACEUTICALS is 3.56.
| Share Price | ₹2,144.4 | Jun 11,2026 |
| Market Cap | ₹60,513.6 Cr | |
| Sales-TTM | ₹16,982.5 Cr | TTM-Consolidated Results |
| Price/Sales | 3.56x | Calculated as Market Cap/Sales |
|---|---|---|
| Explore Stock Analytics | ||
Definition & Calculation of PS (Price/Sales) ratio of GLENMARK PHARMACEUTICALS
P/S =
Market Capitalization
/
Sales
or, using per-share numbers:
P/S = Stock Price / Sales Per Share
Current Market Cap [ ₹60,513.6 Cr] as on Jun 11,2026
(/) Sales [ ₹16,982.5 Cr] based on TTM-Consolidated Results
(=) P/S Ratio [ 3.56x ]
Thus, for GLENMARK PHARMACEUTICALS , the investors are currently willing to pay '3.56 times sales' to own 1 share of the company.
PS Multiples are one of the most widely used valuation multiple in the industry.
P/S ratios can be a reliable benchmark to compare companies with negative earnings or book value.
You may also explore Price to Earnings ratio or Price to Book ratio of GLENMARK PHARMACEUTICALS !
The chart below summarizes the trend in P/S Ratio of GLENMARK PHARMACEUTICALS over the last five years.
Historical PS (Price/Sales) ratio chart of GLENMARK PHARMACEUTICALS
PS Ratio Performance Analysis for GLENMARK PHARMACEUTICALS
- GLENMARK PHARMACEUTICALS 's p/e ratio for fiscal years ending Mar2025 to Mar2021 averaged 1.78x.
- GLENMARK PHARMACEUTICALS 's operated at median p/e ratio of 1.2x from fiscal years ending March 2018 to 2022.
- Looking back at the last 5 fiscal years, GLENMARK PHARMACEUTICALS 's p/e ratio peaked in Mar2025 at 3.26x.
- GLENMARK PHARMACEUTICALS 's p/e ratio hit its five-year low in Mar2022 of 1.01x.
How does GLENMARK PHARMACEUTICALS 's P/S Ratio benchmark against top 10 peers in Pharmaceuticals & Drugs Industry?
| Peer Comparison (Pharmaceuticals & Drugs Industry) | Sales (Cr) | PS Ratio | Market Cap (Cr) |
|---|---|---|---|
| GLENMARK PHARMACEUTICALS | 16,982.5 | 3.56 | 60,513.6 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 58,462.0 | 7.36 | 430,513.0 |
| DIVIS LABORATORIES LTD | 10,560.0 | 16.72 | 176,570.0 |
| TORRENT PHARMACEUTICALS LTD | 13,980.0 | 11.06 | 154,670.0 |
| CIPLA LTD | 28,162.6 | 3.97 | 111,725.0 |
| DR REDDYS LABORATORIES LTD | 33,700.2 | 3.16 | 106,424.0 |
| MANKIND PHARMA LTD | 14,277.6 | 6.86 | 97,948.2 |
| LUPIN LTD | 27,958.0 | 3.72 | 103,975.0 |
| ZYDUS LIFESCIENCES LTD | 27,148.4 | 4.10 | 111,254.0 |
| AUROBINDO PHARMA LTD | 33,653.1 | 2.50 | 84,241.1 |
| LAURUS LABS LTD | 6,812.9 | 11.03 | 75,121.7 |
Pharmaceuticals & Drugs Industry Benchmark (Top 10) PS Analysis vs GLENMARK PHARMACEUTICALS 's P/S Ratio
| Top 10 Industry Peers | PS Ratio |
|---|---|
| Min industry PS | 2.50x |
| Max industry PS | 16.72x |
| Median industry PS | 4.10x |
| Average industry PS | 6.73x |
You may also like the below Video Courses